Implementation of Genetic Screening to Prevent Severe Cutaneous Adverse Drug Reactions Is Crucial—Rebuttal From the Devil’s Antagonist

Abstract

treatments. 2 In contrast to systemic symptoms, this subset of patients with dermatomyositis is characterized by milder inflammatory cutaneous manifestations, usually associated with calcinosis cutis and peripheral edema. Skin disease remission is easier to achieve in these patients 2 compared with those who have long-standing systemic symptoms.In this observation, we describe a rare case of dermatomyositis with Degos-like skin lesions. To our knowledge, the literature contains few other reports of analogous cutaneous manifestations in connective tissue diseases, including dermatomyositis, systemic lupus erythematosus, and systemic sclerosis. 3,4 This case report describes a specific manifestation of dermatomyositis and a phenotypic overlap: both a Degos disease-like presentation and NXP-2 antibodies are indicative of vascular injury with involvement of the gastrointestinal tract. 5,6 Therefore, this case report stimulates future speculation about the interplay between inflammation and autoimmunity, which could translate into a new skin phenotype.

Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions

“…Identifying the type of SCAR is also essential for determining the HLA alleles and the P450 isoforms associated with this hypersensitivity syndrome. The findings of this association will shed light on the predisposing genetic risk factors in SCARs and provide a means for preventive measures, such as a pre-emptive screening of HLA and CYP450 markers before the initiation of drug treatment [ 12 ]. This is in line with the emerging approach of precision medicine where prescribed medication takes individual genetic variability into consideration.…”